Inc. (Little Rock, Arkansas), a biopharmaceutical research and
development company, develops haloperoxidase products for prevention and
treatment of serious infections, to address the growing problem of microbial
drug resistance. The myeloperoxidase (MPO) technology is a versatile platform
that can be leveraged into multiple product areas, including medical,
biodefense, industrial, veterinary, disinfectant, and agricultural applications.
We are committed to integrating our technology with the intellectual,
financial, and commercial strengths of prospective partners to develop
innovative products and long-term relationships.
Exoxemis is a privately held company that draws from academia, private
industry, and government to maximize competitiveness, innovation, and
intellectual capital. Our scientific team spans a wide range of research
and clinical expertise with strong collective credentials in fundamental
research, product development, pre-clinical, and clinical development.
This combined expertise, experience, and demonstrated commitment to both
internal R&D and partnership success enables Exoxemis to bring new
and innovative products to the market.
Exoxemis supplies pharmaceutical-grade haloperoxidase enzymes. Manufacturing processes have been successfully demonstrated and our robust scaleable protein purification process is documented under cGMP requirements. Exoxemis will design and test MPO formulations to produce a steady stream of new products and seeks to commercialize products with partners who complement our capabilities.